Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Holdings Raised by Mizuho Securities USA LLC

Mizuho Securities USA LLC increased its stake in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) by 45.8% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 24,408 shares of the pharmaceutical company's stock after buying an additional 7,671 shares during the quarter. Mizuho Securities USA LLC's holdings in Vertex Pharmaceuticals were worth $9,829,000 as of its most recent SEC filing.

Several other large investors have also added to or reduced their stakes in VRTX. Commerce Bank grew its stake in shares of Vertex Pharmaceuticals by 11.6% during the 3rd quarter. Commerce Bank now owns 7,443 shares of the pharmaceutical company's stock worth $3,462,000 after purchasing an additional 775 shares during the period. Charles Schwab Investment Management Inc. raised its position in Vertex Pharmaceuticals by 1.3% in the third quarter. Charles Schwab Investment Management Inc. now owns 1,626,347 shares of the pharmaceutical company's stock valued at $756,381,000 after purchasing an additional 20,361 shares during the period. Eagle Asset Management Inc. increased its holdings in Vertex Pharmaceuticals by 21.6% in the 3rd quarter. Eagle Asset Management Inc. now owns 8,119 shares of the pharmaceutical company's stock valued at $4,195,000 after purchasing an additional 1,440 shares during the last quarter. Edgewood Management LLC increased its stake in Vertex Pharmaceuticals by 7,876.3% during the third quarter. Edgewood Management LLC now owns 1,546,370 shares of the pharmaceutical company's stock worth $719,186,000 after purchasing an additional 1,526,983 shares during the period. Finally, Covenant Asset Management LLC raised its position in Vertex Pharmaceuticals by 0.9% in the 3rd quarter. Covenant Asset Management LLC now owns 12,764 shares of the pharmaceutical company's stock valued at $5,936,000 after purchasing an additional 118 shares in the last quarter. Hedge funds and other institutional investors own 90.96% of the company's stock.

Remove Ads

Insiders Place Their Bets

In related news, EVP Ourania Tatsis sold 310 shares of the firm's stock in a transaction that occurred on Tuesday, February 11th. The stock was sold at an average price of $459.83, for a total value of $142,547.30. Following the sale, the executive vice president now directly owns 64,021 shares in the company, valued at $29,438,776.43. This trade represents a 0.48 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP David Altshuler sold 3,231 shares of the stock in a transaction on Monday, March 10th. The stock was sold at an average price of $500.00, for a total value of $1,615,500.00. Following the completion of the transaction, the executive vice president now directly owns 26,512 shares of the company's stock, valued at approximately $13,256,000. The trade was a 10.86 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 4,315 shares of company stock valued at $2,121,012. Company insiders own 0.20% of the company's stock.

Vertex Pharmaceuticals Stock Down 1.7 %

Shares of Vertex Pharmaceuticals stock traded down $8.76 during trading hours on Wednesday, hitting $500.28. 1,328,359 shares of the company's stock traded hands, compared to its average volume of 1,222,499. The stock has a 50 day simple moving average of $471.81 and a 200-day simple moving average of $463.08. Vertex Pharmaceuticals Incorporated has a twelve month low of $377.85 and a twelve month high of $519.88. The company has a market cap of $128.47 billion, a PE ratio of -227.40, a PEG ratio of 2.11 and a beta of 0.41. The company has a quick ratio of 2.35, a current ratio of 2.69 and a debt-to-equity ratio of 0.01.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last posted its quarterly earnings results on Monday, February 10th. The pharmaceutical company reported $3.54 EPS for the quarter, missing analysts' consensus estimates of $3.99 by ($0.45). Vertex Pharmaceuticals had a negative return on equity of 2.02% and a negative net margin of 4.86%. Equities research analysts anticipate that Vertex Pharmaceuticals Incorporated will post 15.63 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on the stock. Truist Financial boosted their price target on shares of Vertex Pharmaceuticals from $460.00 to $520.00 and gave the company a "buy" rating in a research report on Tuesday, February 11th. Stifel Nicolaus boosted their target price on shares of Vertex Pharmaceuticals from $490.00 to $494.00 and gave the stock a "hold" rating in a research report on Monday, December 16th. Barclays upped their target price on Vertex Pharmaceuticals from $435.00 to $467.00 and gave the company an "equal weight" rating in a report on Tuesday, February 11th. Cantor Fitzgerald reiterated an "overweight" rating and set a $480.00 target price on shares of Vertex Pharmaceuticals in a report on Tuesday, February 11th. Finally, William Blair reissued an "outperform" rating on shares of Vertex Pharmaceuticals in a research note on Friday, January 31st. Ten analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $506.70.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.